Home medical equipment company AdaptHealth Corp (NASDAQ:AHCO) revealed on Friday that it has entered into a definitive agreement to acquire the Patient Care Solutions (PCS) business from McKesson Corporation.
Subject to customary closing conditions, the acquisition is expected to close in December 2019.
AdaptHealth stated that the total investment, including restructuring costs until the business is fully integrated on AdaptHealth's platform in the latter half of 2020, is anticipated to be approximately USD30m.
PCS provides wound care supplies, ostomy supplies, urological supplies, incontinence supplies, diabetic care supplies and breast pumps directly to patients across the US. The company said it maintains extensive national relationships with physicians, medical facilities and customers, currently serving all 50 states. For the trailing 12 months ended 31 October 2019, it generated net revenues of about USD134m.
Under the terms of the agreement, AdaptHealth will sign a supply and distribution agreement with McKesson Corporation with respect to PCS's HME service lines.
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
OptiBiotix signs distribution deal with major weight management company
GoodRx partners with Novo Nordisk to offer Ozempic and Wegovy at USD499 per month
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial
MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241
Ascletis completes participant dosing in US obesity clinical study
BioLab Holdings' amnion grafts enter multicentre clinical trial
Predictmedix AI launches mobile diabetes screening platform in India
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
BrightGene presents BGM0504 positive Phase 2 data for weight management and type 2 diabetes
Amgen reports results of Phase 2 MariTide obesity study
European Medicines Agency recommends approval of Alvotech's biosimilar to Eylea
Gan & Lee presents trial results for novel diabetes therapies at ADA's 85th Scientific Sessions